ArticleCell host & microbe2018
A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission.
Open access · bronzeAbstract read
In one paragraph
Article in Cell host & microbe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 53 citations in OpenAlex.
- Manipulating Zika virus RNA tertiary structure for developing tissue-specific attenuated vaccines.EMBO molecular medicine · 2025Article
- Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SAInternational journal of molecular sciences · 2024Article
- An Overview of Zika Virus and Zika Virus Induced Neuropathies.International journal of molecular sciences · 2024Review
- A review on Zika vaccine development.Pathogens and disease · 2024Review
- The Dynamic Landscape of Capsid Proteins and Viral RNA Interactions in Flavivirus Genome Packaging and Virus Assembly.Pathogens (Basel, Switzerland) · 2024Review
- A Novel, Comprehensive A129 Mouse Model for Investigating Dengue Vaccines and Evaluating Pathogenesis.Vaccines · 2023Article
- Control of maternal Zika virus infection during pregnancy is associated with lower antibody titers in a macaque model.Frontiers in immunology · 2023Article
- Understanding the Tissue Specificity of ZIKV Infection in Various Animal Models for Vaccine Development.Vaccines · 2022Review
- Zika Virus Infection During Research Vaccine Development: Investigation of the Laboratory-Acquired InfectionFrontiers in cellular and infection microbiology · 2022Review
- From Mosquito Bites to Sexual Transmission: Evaluating Mouse Models of Zika Virus Infection.Viruses · 2021Review
- Enemy of My Enemy: A Novel Insect-Specific Flavivirus Offers a Promising Platform for a Zika Virus Vaccine.Vaccines · 2021Article
- Current Progress in the Development of Zika Virus Vaccines.Vaccines · 2021Review
- Structure and function of capsid protein in flavivirus infection and its applications in the development of vaccines and therapeutics.Veterinary research · 2021Review
- A Live-Attenuated Zika Virus Vaccine with High Production Capacity Confers Effective Protection in Neonatal Mice.Journal of virology · 2021Article
- Evaluation of Vertebrate-Specific Replication-Defective Zika Virus, a Novel Single-Cycle Arbovirus Vaccine, in a Mouse Model.Vaccines · 2021Article
- Generation and preliminary characterization of vertebrate-specific replication-defective Zika virus.Virology · 2021Article
- Replication/Assembly Defective Avian Flavivirus With Internal Deletions in the Capsid Can Be Used as an Approach for Living Attenuated Vaccine.Frontiers in immunology · 2021Article
- Zika structural genes determine the virulence of African and Asian lineages.Emerging microbes & infections · 2020Article
- Review
- The role of capsid in the flaviviral life cycle and perspectives for vaccine development.Vaccine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Xuping XieDepartment of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: xuxie@utmb.edu.
Dieudonné B KumKU Leuven, Rega Institute for Medical Research, Department of Microbiology and Immunology, Laboratory of Virology and Chemoth, University of Leuven, Leuven, Belgium.
Hongjie XiaDepartment of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Huanle LuoDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Chao ShanDepartment of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Jing ZouDepartment of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Antonio E MuruatoDepartment of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Daniele B A MedeirosDepartment of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ministry of Health, Ananindeua, Pará State, Brazil.
Bruno T D NunesDepartment of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ministry of Health, Ananindeua, Pará State, Brazil.
Kai DallmeierKU Leuven, Rega Institute for Medical Research, Department of Microbiology and Immunology, Laboratory of Virology and Chemoth, University of Leuven, Leuven, Belgium.
Shannan L RossiInstitute for Human Infections & Immunity, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology and Center for Biodefense & Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.
Scott C WeaverInstitute for Human Infections & Immunity, University of Texas Medical Branch, Galveston, TX, USA; Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology and Center for Biodefense & Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
Johan NeytsKU Leuven, Rega Institute for Medical Research, Department of Microbiology and Immunology, Laboratory of Virology and Chemoth, University of Leuven, Leuven, Belgium.
Tian WangDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology and Center for Biodefense & Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
Pedro F C VasconcelosDepartment of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ministry of Health, Ananindeua, Pará State, Brazil; Department of Pathology, Pará State University, Belém, Brazil.
Pei-Yong ShiDepartment of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology & Toxicology, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: peshi@utmb.edu.
The University of Texas Medical Branch at Galveston · USKU Leuven · BEInstituto Evandro Chagas · BRMinistério da Saúde · BRRega Institute for Medical Research · BE
Funding
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5MRevolutionary Eilat-based Chikungunya Vaccine VectorR01AI127744 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WANG, TIAN · 2017 to 2021
$3.5MACL HHS U01CK000512NCEZID CDC HHS U01 CK000512NIAID NIH HHS R01 AI127744NIAID NIH HHS R24 AI120942
Abstract
Zika virus (ZIKV) infection of the mother during pregnancy causes devastating Zika congenital syndrome in the offspring. A ZIKV vaccine with optimal safety and immunogenicity for use in pregnant women is critically needed. Toward this goal, we have developed a single-dose live-attenuated vaccine candidate that infects cells with controlled, limited infection rounds. The vaccine contains a 9-amino-acid deletion in the viral capsid protein and replicates to titers of > 10
Indexed as
A549 CellsAnimalsCapsid ProteinsCell LineChlorocebus aethiopsCricetinaeFemaleHumansInfectious Disease Transmission, VerticalMaleMiceMice, Inbred StrainsMice, KnockoutPregnancyVaccines, AttenuatedVero CellsCapsid ProteinsVaccines, AttenuatedViral Vaccinesflavivirus capsidvaccineZika virus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.